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Abstract
Mucinous tubular and spindle cell renal cell carcinoma is a rare, recently described variant of renal cell carcinoma
characterized by an admixture of cuboidal cells in tubules and sheets of spindle cells, and variable amounts of
mucinous stroma. It has been recognized as a distinct entity in the 2004 World Health Organization tumor
classification. Since then, several dozen of these tumor have been reported with additional complementary
morphologic characteristics, immunohistochemical profile, and molecular genetic features that have further
clarified its clinicopathologic aspects. Although originally considered as a low grade renal cell carcinoma on the
basis of its bland appearing nuclear features and indolent clinical course, mucinous tubular and spindle cell renal
cell carcinoma has currently been proven to be a tumor that has a histological spectrum ranging from low to
high grade that includes sarcomatoid differentiation. In this review, we present a detailed summary of the
current knowledge regarding the clinicopathologic, immunohistochemical, molecular genetic, and prognostic
characteristics, as well as differential diagnoses of mucinous tubular and spindle cell renal cell carcinoma.
Introduction
Mucinous tubular and spindle cell renal cell carcinoma
(MTSRCC) is a rare and recently described subtype of
renal cell carcinoma (RCC), which is recognized as a
distinct entity in the 2004 World Health Organization
(WHO) tumor classification [1]. As its descriptive name-
sake has indicated, this tumor is morphologically com-
posed of three salient elements: tubules, spindle cells
and extracellular mucinous/myxoid stroma. Previously,
tumors showing a similar morphology had been referred
to under a variety of rubrics including low-grade collect-
ing duct carcinoma [2], low-grade myxoid renal epithe-
lial neoplasm with distal nephron differentiation [3],
low-grade tubular mucinous renal neoplasm and spindle
and cuboidal renal cell carcinoma [4, 5]. To date, less
than 100 cases of these tumor have been reported in the
English language literature. In this review, we present a
detailed summary of the current knowledge regarding
the clinicopathologic, immunohistochemical, molecular
genetic, and prognostic characteristics, as well as differ-
ential diagnoses of MTSRCC.
Review
Clinical characteristics
MTSRCC predominantly affects adult patients with a wide
age range from 13 to 82 years (mean 53) and shows a fe-
male predominance with a 1:4 male-to-female ratio [6–8].
Although some tumors are symptomatic, such as flank
pain, abdominal mass and hematuria [3], the majority are
discovered incidentally during abdominal imaging studies
for other unrelated reasons [9]. An association with
nephrolithiasis [5] and those arising from the background
of end stage renal disease have been noted [10]. Radio-
logically, MTSRCC displays a common appearance that is
different from clear-cell RCC but similar to papillary RCC
[11]. It usually presents as a well-demarcated, exophytic
or partially exophytic renal mass and showes an expansile
growth pattern with a spherical or ovoid shape on com-
puted tomograph scan. Tumors less than 5-cm usually
demonstrate homogenous pattern of enhancement while
those larger than 5-cm often show heterogeneous en-
hancement pattern [11].
Pathological findings
Grossly, the epicenter of MTSRCC is usually located in
renal cortex. The tumors are generally well circumscribed
and partially encapsulated, with a wide size range from
less than 1-cm diameter to greater than 18-cm. The cut
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surface is commonly bulging, shiny and mucoid, with a
uniform homogenous tan, gray or pale yellow color and
a solid consistency [7, 9, 8, 12] (Fig. 1). Foci of
hemorrhage and/or necrosis may be seen, but these are
uncommon [7].
Histologically, the tumor is characterized by a mixture
of tubular and spindle cell components separated by
variable amounts of mucinous stroma [12, 7, 8] (Fig. 2).
The tubules are round, ovoid, or elongated with a col-
lapsed central lumen, they are usually tightly packed and
parallelly arranged, and sometimes merge into cord-like
structures or even form a solid growth pattern (Fig. 2a).
Transitions between the elongated tubules and the spindle
cells are commonly seen, and in some tumors the spindle
cell areas can be the dominant component, at times re-
sembling a mesenchymal neoplasm such as leiomyoma or
myofibroblastoma [13] (Fig. 2b). Papillation projections
with tumor cell tufts protruding into the tubular lumen,
and true papilla with well-shaped fibrovascular cores can
be seen as a minor component [14, 13, 15–17, 6, 18],
and rarely, as a prominent component [19] in MTSRCC.
Extracellular blue-gray mucinous/myxoid matrix are
usually abundant in the majority cases of MTSRCC,
sometimes these mucinous collections may appear as nu-
merous small vacuoles partially obscuring the MTSRCC
architecture and mimicking clear cells [13] (Fig. 2c). A so-
called “mucin-poor” pattern of MTSRCC has recently
been described where there is little or no extracellular
mucin that can be appreciable on routine microscopy
(Fig. 2d), in this setting, Alcian blue stain can highlights
the scant mucin in the tumor [13, 20]. Cytologically, the
tumor cells are usually bland-appearing with scant, pale to
slightly eosinophilic cytoplasm and indistinctive borders.
Rarely, minor areas with clear cell and oncocytic changes
have been reported [13, 17, 21] (Fig. 3a). The nuclei are
generally round, uniform and display low nuclear grade
characteristics with evenly dispersed chromatin and in-
conspicuous nucleoli corresponding to Fuhrman nuclear
grade 2, but occasionally high nuclear grade change may
be observed [22–25] (Fig. 3b). Mitoses are rare and necro-
sis is uncommonly seen. Examples of MTSRCC with
sarcomatoid differentiation characterized by high-grade
spindle cell proliferation with marked cytologic atypia,
tumor necrosis, and increased mitotic activity have been
recently reported [26–29] (Fig. 3c). In additional to myx-
oid degeneration, other common and not-so-common
stromal changes that can be seen in MTSRCC include ag-
gregations of foamy macrophages (Fig. 3d), cuffing infiltra-
tions of lymphoplasmacytic cells surrounding the tumor
cell nests (Fig. 3e), depositions of small psammoma bodies
(Fig. 3f), and heterotopic bone formation.
Immunohistochemical findings
Immunohistochemical studies of MTSRCC show that
the neoplastic cells of both the tubules and spindle
cells stain consistently positively for PAX2/8, low mo-
lecular weight cytokeratins (CK8/18, CK19 and CK7)
(Fig. 4a), epithelial membrane antigen (EMA), alpha-
methylacyl-CoA racemase (AMACR) (Fig. 4b), and E-
cadherin [30, 14, 15]. Staining for vimentin (Fig. 4c)
and high molecular weight cytokeratin (34BE12) show
variable expression, and RCC maker, CD10 and CD15
are often negative but occasionally be positive [15, 16],
while staining for carbonic anhydrase IX, ulex euro-
paeus agglutinin (UEA-1), P63, CK20, GATA3 and
smooth muscle actin (SMA) are typically negative [30]
(Table 1). Recently evidence of MTSRCC with neuro-
endocrine differentation, with tumor cells immuno-
staining for chromogranin A (Fig. 4d), synaptophysin,
and neuron-specific enolase, have been reported, and
in some cases supported by ultrastructural findings
[31–33].
Histogenesis and molecular genetics
The ontogenic identity of epithelial nature between the
tubular and spindle cell component in MTSRCC has
been well established by immunohistochemisty, how-
ever, the exact renal epithelial cell line of differentiation
remains debatable [15]. Although MTSRCC was ini-
tially considered to originate from either cells of the
loop of Henle or collecting duct epithelium [2, 3, 34],
accumulated evidence showing complex immunoprofile
Fig. 1 Gross appearance of MTSRCC. The tumor is usually well-
demarcated with a homogeneous, gray to white, often bulging and
shiny mucoid cut surface
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with uniform expression of CK7 and AMACR suggests
its proximal nephron origin and intimate relationship
to papillary RCC [15, 16, 7]. Indeed, some authors have
suggested that MTSRCC may represents a variant of
papillary RCC [16, 18], and in some settings, make a
confident distinction between these two entities based
on routine microscopy and immunohistochemistry may
be impossible and often requires molecular genetic
studies [8].
Genomic investigations for MTSRCC, mainly in sin-
gle case or small series studies and based on karyotyp-
ing, comparative genomic hybridization (CGH), and
fluorescent in situ hybridization (FISH) analyses, have
demonstrated multiple chromosomal numerical aber-
rations in these tumors, with losses of (or partly from)
chromosomes 1, 4, 6, 8, 9, 11, 13, 14, 15, 18, 22 and X,
as well as gains of all or parts of chromosomes 2, 3, 4,
5, 7, 9, 10, 12, 15, 16, 17, 18, 19, 20, 22 and Y [3, 4, 14,
35, 28, 24] (Table 2). Most recently, Peckova et al. [25]
who investigated hitherto the largest series of MTSRCC
for molecular genetic abnormalities using CGH analysis
found that both the low grade and high grade MTSRCC
of classic morphology showed chromosomal losses includ-
ing 1, 4, 6, 8, 9, 13, 14, 15, and 22 without any chromo-
somal ganis detected, while those showing morphologic
features overlapping with papillary RCC demonstrated a
more variable pattern with multiple chromosomal losses
and gains, including gains of chromosomes 7 and 17 in
two of the four analyzable tumors. However, FISH-
based analyses have consistently proved that MTSRCC
lacks of the the gains of chromosomes 7 and 17 and
losses of chromosome Y that are characteristic of papil-
lary RCC [36, 19]. These emerging evidence suggests
that MTSRCC is histologically heterogenous tumor that
can shows morphologic and immunohistochemical fea-
tures overlapping with papillary RCC, but genetically
distinctive entity different from papillary RCC.
Differential diagnosis
MTSRCC in its classic form is so distinctive that there
should be no diagnostic problem, however, when vari-
ant patterns of the tumor are seen, such as predomin-
ance of spindle cells, paucity of mucin, diagnostic
difficulties may arise, particularly on needle biopsies
when pathologists are providing with only tiny mate-
rials. With regard to MTSRCC where spindle cells
dominate, the most critical differential diagnosis is sar-
comatoid RCC, which can develops in any form of
RCC and usually confers an aggressive behavior. The
spindle cells in MTSRCC are bland-looking with uni-
form architectural pattern and usually low nuclear
grade, lacking large, hyperchromatic/pleomorphic nu-
clei, significant mitotic activity or sheet of necrosis
which are prevalent in sarcomatoid RCC. MTSRCC
Fig. 2 Microscopic features of MTSRCC. a The tumor is composed of elongated tubules and spindle cells that are separated by abundant
basophilic extracellular mucinous stroma. b When spindle cells dominate, this tumor may mimics a mesenchymal tumor. c Occasionally,
mucinous collections may appear as numerous small vacuoles (arrow) imparting an appearance of clear cells. d Depicting a mucin-poor pattern
of MTSRCC
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itself can experiences sarcomatoid transformation [28],
however, in these tumors, at least focally, evidence of a
low grade component exists. Spindle cell predominant
MTSRCC may be confused with mesenchymal neoplasms
such as smooth muscle tumors (both leiomyoma and leio-
myosarcoma), and inflammatory myofibroblastic tumor
(IMT) when infiltrated by severe chronic inflammations.
However, both smooth muscle tumors and IMT usually
have a more distinct fascicular arrangement and more
elongated nuclei, and label strongly with SMA and
rarely with cytokeratins. Lastly, as above have men-
tioned, overlapping morphologic features with papillary
RCC can make the distinction between MTSRCC and
papillary RCC difficult. Type 1 papillary RCC in areas
can adopts a solid growth pattern with compression of
elongated tubules and papillae which imparts a fusiform
architecture mimicing MTSRCC. However, papillary
RCC usually has a predominantly tubulopapillary pattern
with complex branching papilla containing well-deformed
fibrovascular cores and lacks of mucinous stroma which
usually extensively and at least focally exist in MTSRCC.
Immunocytochemistry in distinguishing papillary RCC
from MTSRCC is largely unhelpful because the two en-
tities share a CK7 and AMACR positive profile, although
CD10 is less likely to be reactive in MTSRCC than in pap-
illary RCC [15]. Recently, a so-called papillary RCC with
low grade spindle cell foci has been described which can
shows morphology significantly resembling MTSRCC
[37]. In contrast to MTSRCC, this tumor is characterized
by a male predominance and foci of bland-appearing spin-
dle cells dispersed among more conventional looking
papillary RCC. As this tumor dispalys the typical gains of
Fig. 3 Uncommon histologic features of MTSRCC. a Foci of clear cell changes. b High grade MTSRCC with prominent nucleoli corresponding to
Fuhrman grade 3. c MTSRCC with sarcomatoid transformation (left, sarcomatoid component; right, mucin-poor MTSRCC). d Aggregations of foamy
macrophages (arrow). e Cuffing infiltrations of lymphoplasmacytic cells. f Depositions of small psammoma bodies (arrow)
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chromosomes 7 and 17 associated with papillary RCC,
FISH analysis can be used to clinch the diagnosis if
needed [37].
Prognosis and therapy
The prognosis for MTSRCC with classic morphology is
generally favorable and complete surgical excision ap-
pears to be adequate treatment [1]. These tumors are
generally of low pathological stage (pT1, pT2) at diag-
nosis and are amenable to partial or radical nephrec-
tomy. Few cases have demonstrated tumor recurrence,
regional lymph nodes and distant sites metastases, as
well as tumor-associated deaths [3, 5, 4, 14, 26, 28, 38,
39]. Metastasis usually occurs in tumors with atypical
histological features such as high nuclear grade and
sarcomatoid transformation, however, cases with clas-
sic, low-grade morphology of MTSRCC developing
multiple distant metastases with both the primary
tumor and metastases displaying identical morphology
have also been reported [38, 39]. It is therefore recom-
mended that although an innocent outcome is likely, a
close follow-up is warranted. With regard to the ther-
apy of MTSRCC, patients with localised disease are
usually treated with resection, either partial or radical
nephrectomy. For metastatic diseases, there are no re-
ports of systemic treatment guideline published to date.
Most recently one case of metastatic MTSRCC showing
a response to sunitinib has been documented [40].
Table 1 Summary of immunohistochemical staining profile of MTSRCC
Authors (yr) No. cases AMACR AE1/AE3 CK7 CK19 EMA Vimentin RCC maker CD10 CD15 HMWCK E-cadherin
Parwani et al. (2001) [3] 4 NA 4/4 4/4 0/4 4/4 4/4 NA NA 0/4 4/4 NA
Rakozy et al. (2002) [4] 5 NA 5/5 NA 4/5 5/5 2/5 0/5 NA NA NA NA
Hes et al. (2002) [5] 11 NA 11/11 9/9 NA 11/11 11/11 NA NA 0/11 NA NA
Ferlicot et al. (2005) [14] 15 12/12 13/13 14/14 13/13 14/14 2/14 5/11 3/14 4/14 3/14 10/11
Paner et al. (2006) [15] 27 25/27 NA 22/27 NA 19/20 NA 2/27 4/27 NA 4/26 NA
Fine et al. (2006) [13] 17 9/13 NA 12/13 NA NA NA NP NA NA NA NA
Shen et al. (2007) [16] 12 11/12 NA 11/12 NA NA NA 11/12 6/12 11/12 NA NA
Wu et al. (2014) [6] 8 7/8 NA 5/8 NA 3/8 6/8 NA NA NA NA NA
HMWCK high molecular weight CK, NA not available
Fig. 4 Immunohistochemical features of MTSRCC. The neoplastic cells of both the tubules and spindle cells stain consistently positively for (a)
CK7 and (b) AMACR. Most cases stain positively for (c) vimentin. A minority of cases may show neuroendocrine differentiation, as depicted here,
express (d) chromogranin A
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Conclusions
Although a close relationship to papillary RCC has been
suggested, on the basis of clinical, morphological as well
as molecular genetic data, we consider MTSRCC to be a
separate and distinct renal neoplastic entity. This tumor
has a histological spectrum ranging from low to high
grade that includes sarcomatoid differentiation which
can confers the tumor an aggressive clinical course.
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